Table 2.

Pre-clinical and clinical studies on Molnupiravir.

Model	Number of patients or animals (F/M)	Intervention	Follow up	Phase	Ref
In vivo: hamsters	SG hamsters (F)	Molnupiravir	4 days	–	[133]
In vitro: VeroE6 Huh7 HtAEC HsAEC		Remdesivir EIDD-1931 AT-511 GS-441524 IFN (β1and λ1)			[134]
In vitro: A549-hACE2		Molnupiravir Ribavirin Favipiravir			[135]
In vivo: Immunodeficient mice implanted with human lung tissue		Molnupiravir	2 days		[120]
Humans	103	Molnupiravir	28–30 days	Phase I	[122]
In vitro		Pibrentasvir Ombitasvir Sofosbuvir Remdesivir Favipiravir Molnupiravir AT-527			[136]
Humans	64 (53 M/11 F)	Molnupiravir	14 days	Phase 1	[118]
Humans	202 (98 M/104 F)	Molnupiravir	28 days	Phase 2a	[137]
In vivo: Syrian hamsters	12	Molnupiravir	4 days		[138]
In vivo: Ferrets		Molnupiravir	4 & 10 days		[139]
In vivo: Mice		Molnupiravir	5 days		[116]
In vitro: Human airway epithelial cell		Molnupiravir